Pharma news
Americas
Eli Lilly appears to be mulling whether to oppose a trademark registered by Bristol-Myers Squibb at the US Patent and Trademark Office. 21 November 2017
Pharma
The English High Court has refused to grant Eli Lilly an injunction which would have stopped Teva, Actavis and Mylan marketing a generic version of its drug Cialis (tadalafil). 17 November 2017
Americas
NPS Pharmaceuticals suffered a knock-back yesterday, when the US Court of Appeals for the Federal Circuit affirmed a decision which found that claims covering a patent owned by NPS were unpatentable. 16 November 2017
Pharma
Swiss-type second medical use patents can be infringed if a generic producer could have reasonably foreseen that its product would be used intentionally for the claimed use, according to the Supreme Court of the Netherlands. 14 November 2017
Americas
On November 7, the House Judiciary Committee’s subcommittee on IP took part in the “Sovereign Immunity and the Intellectual Property System” hearing. 13 November 2017
Americas
Major tasks for Carl Gordon of OrbiMed, a healthcare fund, include drug pricing and helping to turn promising ideas into reality, as he tells LSIPR. 10 November 2017
Pharma
Thomas Kirkbak, chief IP litigation specialist at Danish company Lundbeck, faces challenges on several fronts, as he explains to LSIPR. 10 November 2017
Americas
In the current IP landscape it is wise to be prepared for attacks on important patents, as Lars Kellberg, corporate vice president and corporate patents of Novo Nordisk, explains to LSIPR. 10 November 2017
Pharma
Pharmaceutical company UCB injects a significant amount of revenue into R&D, but it is mindful of the risks attached to drug investment. Global head of IP Stéphane Drouin explains more in an interview with LSIPR. 10 November 2017
Pharma
Richard Henderson, an award-winning scientist based in Cambridge, UK, is seeking to make his next important discovery in the field of biological electron microscopy, as LSIPR finds out. 10 November 2017